Biomagnetics Receives Delivery of World’s First Integrated Optical Biosensor for Disease Diagnosis from Los Alamos Nationa

SAN FRANCISCO--(BUSINESS WIRE)-- Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP - News) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has accepted delivery of the world’s first integrated optical biosensor for disease diagnosis. This new type of diagnostic device was developed in conjunction with the scientists and engineers at Los Alamos National Laboratory. The Company now plans to proceed with the process of ministration and commercialization of this groundbreaking technology.

IOBS-1 (Photo: Business Wire)

IOBS-1 (Photo: Business Wire)

Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. commented, “Today, the integrated optic biosensor moves out of the theoretical world of the laboratory into our possession. It is amazing that a device with such wide scale capabilities has been developed and delivered to our company. An integrated optical biosensor device holds the promise to allow relatively untrained medical personnel to diagnose a variety of diseases in a matter of only a few minutes. We will be proceeding with our plans to reengineer the technology into a format that can be utilized for clinical trials and commercialization later this year.”

About Biomagnetics Diagnostics Corp.

Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company and an acquirer of other innovative technologies. The Company is currently developing a waveguide-based advanced integrated optical biosensor through its cooperative research and development agreement with Los Alamos National Security, LLC, which will initially be used for cholera, tuberculosis and malaria diagnosis. More information on Biomagnetics Diagnostics Corp. can be seen at www.biomagneticsbmgp.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6696743&lang=en



CONTACT:

Investor Relations Contact:
Equiti-trend Advisors, LLC, 800-953-3350

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Technology  Hardware  Health  Biotechnology  Infectious Diseases  Medical Devices  Pharmaceutical  Research  Science

MEDIA:

Photo
 Photo
IOBS-1 (Photo: Business Wire)
Photo
 Photo
IOBS-2 (Photo: Business Wire)

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.